Medtronic Medical Device Company Intelligence Report

Date: March 7, 2013
Pages: 96
US$ 515.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Medtronic Medical Device Company Intelligence Report
Founded in 1949, Minnesota, US-based Medtronic has grown to become a leading developer and manufacturer of medical devices designed to diagnose, prevent and monitor chronic conditions. Beginning with the development of the heart pacemaker in the 1950s, the company has assembled a broad and diverse portfolio of progressive technology expertise both through internal development of core technologies and acquisitions.

Medtronic’s primary products include those used for the treatment of cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose and throat conditions. The company operates under two principal business segments:

The Cardiac and Vascular Group (composed on the Cardiac Rhythm Disease Management [CRDM] and CardioVascular businesses), whose product portfolio includes pacemakers, implantable defibrillators, leads and delivery systems, ablation products, electrophysiology catheters, products for the treatment of atrial fibrillation (AF), information systems for the management of patients with CRDM devices, coronary and peripheral stents and related delivery systems, therapies for uncontrolled hypertension, endovascular stent graft systems and heart valve replacement technologies.

In January 2012, Medtronic sold its Physio-Control business, previously part of the CardioVascular group, which offered a portfolio of external defibrillation and emergency response systems, data management solutions and support services. Since Medtronic and Physio-Control’s core businesses and customers are significantly different, both parties believed that Physio-Control will be able to move more quickly, be more competitive and have more direct focus on its customers as a separate entity.

The Restorative Therapies Group (composed of the Spinal, Neuromodulation, Diabetes and Surgical Technologies businesses), which offers products for various areas of the spine, bone graft substitutes, biologic products, implantable neurostimulation therapies and drug-delivery devices for the treatment of chronic pain, movement disorders, obsessive compulsive disorder, overactive bladder, urinary retention and gastroparesis; external insulin pumps; subcutaneous continuous glucose monitoring systems; and products to treat conditions of the ear, nose and throat. Additionally, this group manufactures and sells primarily image-guided surgery and intra-operative imaging systems, energy systems and haemostatic sealing products.

Medtronic conducts its business in more than 120 countries worldwide. In fiscal year (FY) 2012 (ended April 2012), the company generated sales of US$16.18 billion and employed approximately 45,000 people worldwide.

In FY2012, Medtronic made progress in positioning itself to succeed in the dynamic healthcare market. Revenue growth improved modestly from 1% in FY2011 to 4% in FY 2012. Three-quarters of the business posted strong performance, growing by a combined 10%. The remaining businesses, consisting of the US Implantable Cardioverter Defibrillator and US Spine businesses, declined by 10%. While these businesses had unique factors affecting their performance, both showed some signs of stabilisation by the end of FY2012. International revenue grew by 11% while emerging markets grew by 20% in constant currency, and 19% as reported.

In FY2012, Medtronic gained market share in the majority of its businesses, driven by a series of product launches. The Resolute Integrity drug-eluting stent, the RestorSensor spinal cord stimulator and the Endurant II AAA stent graft system are all expected to drive further growth in FY2013.

This company report provides

  • Key contact information
  • Introduction to the company and its current activities
  • Summary of its financial performance
  • Who are the company’s major competitors?
  • Key recent events in an “at a glance” format
Financial Review
  • Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
  • Table providing in-depth five-year financial analysis
  • Employee data, including breakdown by company division and geographic location
Strategic Focus
Investigates the company’s aims and its areas of focus

Core product areas, key brands, product approvals and launches Research and Development
  • How much has been invested in R&D?
  • Where is the research based?
  • What alliances and agreements does the company have and with whom?
Manufacturing and Distribution
  • Identifying the company’s manufacturing locations
  • Sales and marketing facilities
  • With whom has the company reached agreements and what do they involve?
  • Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments


Key Corporate Events

  Recent Key Events


Demonstrating Economic Value
  Growth Drivers
    Product Launches
    Portfolio Management
    Market Growth
     Other Emerging Markets
Espicom View


Fiscal Year 2012 Financial Results
  Cardiac and Vascular Group
  Restorative Therapies Group
    Surgical Technologies
Five-Year Financial Data


Cardiac and Vascular Group
    Implantable Cardiac Pacemakers
    Implantable Cardioverter Defibrillators (ICDs)
    Cardiac Resynchronisation Therapy with Defibrillation (CRT-Ds)
    Atrial Fibrillation (AF)
    Diagnostics and Monitoring
    Patient Management Tools
    Percutaneous Coronary Intervention (PCI)
    Renal Denervation
  Endovascular and Peripheral
    Peripheral Vascular Intervention (PVI)
    Endovascular Stent Grafts
  Structural Heart Disease
    Heart Valves
    Transcatheter Heart Valves
    Arrested Heart Surgery
    Beating Heart Surgery
    Surgical Ablation
Restorative Therapies Group
    Thoracolumbar Products
    Kyphon Balloon Kyphoplasty
     Cervical Products
  Neurostimulators for Chronic Pain
  Implantable Drug Delivery Systems
  DBS Systems
  Urology, Faecal and Gastro-enterology Devices
  Integrated Diabetes Management Solutions
     Blood Glucose Meters
     CareLink Therapy Management Software
  Surgical Technologies
     Neurological Technologies
     Navigation and Imaging


R&D Activities and Expenditure
Studies and Trials


Sales & Distribution


  Miami Instruments
  Acorda Therapeutics
  Bayer HealthCare
  Eli Lilly
  Nile Therapeautics
  Alnylam Pharmaceuticals and CHDI Foundation
  Ziehm Imaging
  West Wireless Health Institute
  Thermal Scalpel (Acacia Research)
  Eli Lilly
  Cardio Access (Acacia Research)


  China Kanghui Holdings
  PEAK Surgical and Salient Surgical Technologies
  Adelaide Research & Innovation, Robinson Squidgel and Otago Innovation assets ���������������������������������������������������������69
  Unidentified Company
  ATS Medical
  Axon Systems
  Ventor Technologies
  Ablation Frontiers
  Influent Medical’s Repose Product Line
  CryoCath Technologies
  Pabban Development
  Restore Medical


  LifeTech Scientific
  Mainstay Medical
  Inspire Medical Systems
  GI Dynamics
  Proteus Biomedical


  MD Start
  Medtronic Weigao Orthopaedic Device Co Ltd
  MG Biotherapeutics


  Physio-Control Business
  Bravo pH Monitoring Business for Diagnosing GORD
  Memphis, Tennessee, Production Facility
  Magellan Platelet Business
  Neurodiagnostic Product Line
  Gastro-enterology Diagnostic Product Line
  Tonometry Products


  Minneapolis Firefighters Relief Association
  US Department of Justice
  Jennifer English – Personal Injury Lawsuit
  Bovie Medical
  Globus Medical
  Edwards Lifesciences
  AGA Medical
  Wyeth and Cordis
  Sprint Fidelis Product Liability Matters



    Medtronic - FY2012 Changes
    Espicom Analysis of the Chinese Medical Device Market, 2012
    Medtronic - Annual Financial Results, FY2008-FY2012
    Medtronic - Annual Net Sales by Geographic Area, FY2008-FY2012
    Medtronic - Annual Sales by Product Segment, FY2009-FY2012
    Medtronic – Five-Year Financial Summary, FY2008-FY2012
    Selected Medtronic Trials and Studies
    Medtronic’s Key Manufacturing Centres
    Agreements Summary
    Mergers and Acquisitions Summary


    Medtronic - Annual Net Sales and Operating Income, FY2008-FY2012
    Medtronic - Annual Net Sales by Geographic Area, FY2008-FY2012
    Medtronic - Annual Net Sales by Product Area, FY2000-FY2012
    Medtronic - FY2012 Sales by Product Segment
    Medtronic – Annual CRDM Product Sales, FY2009-FY2012
    Medtronic - Annual CardioVascular Product Sales - FY2009-FY2012
    Medtronic – Annual Spinal Product Sales – FY2009-FY2012
    Medtronic - Annual Neuromodulation Product Sales, FY2009-FY2012
    Medtronic - Annual Diabetes Product Sales, FY2009-FY2012
    Medtronic - Surgical Technologies Annual Sales – FY2009-FY2012 (US$ million)
Skip to top

Covidien Medical Device Company Intelligence Report US$ 515.00 Apr, 2013 · 42 pages
Medical Device Company Performance Tables US$ 690.00 Mar, 2010 · 414 pages
St Jude Medical Device Company Intelligence Report US$ 515.00 Jul, 2013 · 46 pages

Ask Your Question

Medtronic Medical Device Company Intelligence Report
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: